Clinuvel Pharmaceuticals (CUVL) vs Larimar Therapeutics (LRMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Clinuvel Pharmaceuticals (CUVL) has outperformed Larimar Therapeutics (LRMR) over the past year, losing 29.7% versus a loss of 41.7%. Over five years, LRMR leads with a -77.3% price change compared with -80.9% for CUVL. Clinuvel Pharmaceuticals is the larger company by market cap ($292.8 million vs $285.7 million), about 1.0 times the size.
Clinuvel Pharmaceuticals pays a dividend yielding 0.86%, while Larimar Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUVL | LRMR |
|---|---|---|
| Share price | $5.80 | $2.75 |
| Market cap | $292.83M | $285.68M |
| 1-day change | +2.29% | -1.08% |
| YTD return | -31.60% | -27.82% |
| 1-year return | -29.70% | -41.74% |
| 5-year return | -80.95% | -77.31% |
| P/E ratio (TTM) | 12.61 | — |
| EPS (TTM) | $0.46 | $-1.99 |
| Dividend yield | 0.86% | 0.00% |
| Annual dividend | $0.05 | $0.00 |
| 52-week high | $8.92 | $6.42 |
| 52-week low | $5.57 | $2.72 |
| Distance from 52-week high | -34.98% | -57.17% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +423.64% |
| Average volume | 13.00K | 1.32M |
| Shares outstanding | 50.49M | 103.88M |
| Employees | — | 71 |
| Sector | Miscellaneous | Health Care |
| Industry | Miscellaneous | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CUVL has outperformed LRMR by 12.0 percentage points over the past year.
- The two companies sit in different sectors: Clinuvel Pharmaceuticals in Miscellaneous and Larimar Therapeutics in Health Care.
About Clinuvel Pharmaceuticals
CUVL stock →Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Miscellaneous · Miscellaneous
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
CUVL vs LRMR FAQ
Which is bigger, Clinuvel Pharmaceuticals or Larimar Therapeutics?
Clinuvel Pharmaceuticals (CUVL) is larger, with a market capitalization of $292.83M compared with $285.68M for Larimar Therapeutics (LRMR).
Which stock has performed better over the past year, CUVL or LRMR?
CUVL returned -29.70% over the past 12 months, compared with -41.74% for LRMR (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Clinuvel Pharmaceuticals or Larimar Therapeutics?
Clinuvel Pharmaceuticals pays a dividend yielding 0.86%, while Larimar Therapeutics does not currently pay a regular dividend.
Are Clinuvel Pharmaceuticals and Larimar Therapeutics in the same industry?
No. Clinuvel Pharmaceuticals is in the Miscellaneous sector, while Larimar Therapeutics is in Health Care.